Moderna, Inc. has announced that it will present five abstracts related to its investigational mRNA therapeutics at the upcoming 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The event is scheduled to take place from September 2-6, 2025, at the Kyoto International Conference Center in Kyoto, Japan.
This presentation marks a significant milestone for Moderna, as it will showcase data for the first time concerning its programs for methylmalonic acidemia (MMA) and Glycogen Storage Disease Type 1a (GSD1a). The accepted abstracts include three oral presentations and two poster presentations, focusing on the company’s advancements in treating propionic acidemia (PA), MMA, and GSD1a.
The inclusion of these presentations highlights Moderna’s ongoing commitment to addressing rare metabolic disorders through innovative therapies. The company’s research aims to provide new treatment options for patients suffering from these complex conditions.
As mRNA technology continues to evolve, Moderna’s work at this congress seeks to engage the scientific community in discussions about the potential applications of mRNA therapeutics in metabolic diseases. The presentations are expected to contribute valuable insights and foster collaborative efforts in the field.
The ICIEM serves as a global platform for experts to share research findings and explore advancements in the understanding and treatment of inborn errors of metabolism. Moderna’s participation underscores the importance of ongoing research and innovation in this area.
Details regarding the specific content of the presentations will be disclosed during the congress, allowing attendees to gain a deeper understanding of the implications of Moderna’s findings for future therapeutic developments.
